Results 151 to 160 of about 37,460 (168)
Multi-epitope immunocapture of huntingtin reveals striatum-selective molecular signatures. [PDF]
Mol Syst BiolJustice JL +6 more
europepmc +1 more source
Comparisons of neurodegenerative disease biomarkers across different biological fluids from patients with Huntington's disease. [PDF]
J NeurolBamford AR +3 more
europepmc +1 more source
Effects of Macromolecular Cosolutes on the Kinetics of Huntingtin Aggregation Monitored by NMR Spectroscopy. [PDF]
J Phys Chem LettTorricella F, Tugarinov V, Clore GM.
europepmc +1 more source
Luteolin as potential treatment for Huntington's disease: Insights from a transgenic mouse model. [PDF]
CNS Neurosci TherMohammed A +9 more
europepmc +1 more source
Stereopure ASOs: An unanticipated increase in selectivity for targeting mutant HTT. [PDF]
Mol Ther Nucleic AcidsGulumkar VN, Dowdy SF.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Calretinin interacts with huntingtin and reduces mutant huntingtin‐caused cytotoxicity
Journal of Neurochemistry, 2012AbstractHuntington's disease (HD) is a devastating neurodegenerative disorder caused by an expansion of CAG trinucleotide repeats encoding for polyglutamine (polyQ) in the huntingtin (Htt) gene. Despite considerable effort, the mechanisms underlying the toxicity of the mutated Htt protein remains largely uncertain. To identify novel therapeutic targets,
Khosrow Rezvani +11 more
openaire +3 more sources
New England Journal of Medicine, 2012
Huntington's disease was the first disease whose causative gene (HTT) was mapped to a chromosome, and yet almost 30 years later, rational treatments do not exist. A recent study using a mouse model supports a strategy to knock down HTT RNA.
Neil Aronin, Melissa J. Moore
openaire +3 more sources
Huntington's disease was the first disease whose causative gene (HTT) was mapped to a chromosome, and yet almost 30 years later, rational treatments do not exist. A recent study using a mouse model supports a strategy to knock down HTT RNA.
Neil Aronin, Melissa J. Moore
openaire +3 more sources
2014
Huntingtin (HTT) is the 3,144–amino acid protein product of the Huntington’s disease gene (HTT), which can be traced back through 800 million years of evolution. It carries a trinucleotide CAG repeat that encodes polyglutamine (polyQ) at an evolutionarily conserved NH2-terminal position in exon 1. This chapter discusses the discoveries that have mapped
C. Zuccato, E. Cattaneo
openaire +3 more sources
Huntingtin (HTT) is the 3,144–amino acid protein product of the Huntington’s disease gene (HTT), which can be traced back through 800 million years of evolution. It carries a trinucleotide CAG repeat that encodes polyglutamine (polyQ) at an evolutionarily conserved NH2-terminal position in exon 1. This chapter discusses the discoveries that have mapped
C. Zuccato, E. Cattaneo
openaire +3 more sources
Science, 2001
Huntington9s disease (HD) is a neurodegenerative disease caused by an expanded run of glutamine repeats in the huntingtin protein. How this glutamine expansion results in the selective loss of striatal neurons characteristic of HD is not known. In a Perspective, Trottier and Mandel discuss new findings demonstrating that loss of the beneficial ...
Trottier, Yvon, Mandel, Jean Louis
openaire +3 more sources
Huntington9s disease (HD) is a neurodegenerative disease caused by an expanded run of glutamine repeats in the huntingtin protein. How this glutamine expansion results in the selective loss of striatal neurons characteristic of HD is not known. In a Perspective, Trottier and Mandel discuss new findings demonstrating that loss of the beneficial ...
Trottier, Yvon, Mandel, Jean Louis
openaire +3 more sources